Profits before patients

Making a cheap drug expensive: Biotech giant Genzyme recently discolsed plans to pull it’s lukemia treatment Campath (alemtuzumab) from world-wide markets, in anticipation of ending its off-label, relatively inexpensive use as a treatment for multiple sclerosis. With plans in the works for the unveiling of a re-labeled,  but essentially unchanged version marketed specifically as an MS treatment under the name Lamtrada, Genzyme seeks to boost their profits from the drug from a measly $76 million to a much more satisfying $400 million. Genzyme is currently offering Campath to leukemia patients often at no charge, but is only allowing access to MS patients, for now, through clinical trials. It is estimated that the cost of Lamtrada could be as much as 20 times the cost of Campath. Multiple sclerosis patients already using Campath will find it no longer available until the far more expensive version is approved for sale. Read more at YCharts.


Author: stephen

stephen harris is a writer, painter and a photographer who lives with his family in maine.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s